Merck gives response data for Keytruda in head and neck cancer

Merck & Co Inc said that its checkpoint antibody Keytruda (pembrolizumab) achieved an overall response rate of 25% in patients with metastatic head and neck cancer. The Phase 1b study included 132 heavily pre-treated patients.